ZICX:OTO-Zicix Corporation (USD)

COMMON STOCK | Software - Application | OTC Pink

Last Closing

USD 0.001

Change

0.00 (-16.67)%

Market Cap

USD 0.02B

Volume

0.23M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Zicix Corp provides medical diagnostic services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Software - Application

Symbol Name Price(Change) Market Cap
SAPGF SAP SE

+0.90 (+0.41%)

USD 247.42B
CNSWF Constellation Software Inc

+4.34 (+0.14%)

USD 65.47B
WTCHF WiseTech Global Limited

N/A

USD 27.86B
DIDIY Didi Global Inc ADR

-0.04 (-1.02%)

USD 18.88B
XROLF Xero Limited

N/A

USD 14.77B
SGGEF The Sage Group plc

N/A

USD 13.04B
NEMKY Nemetschek SE

N/A

USD 11.31B
LMGIF Lumine Group Inc.

-0.92 (-3.55%)

USD 6.66B
TMSNY Temenos Group AG ADR

+1.45 (+2.03%)

USD 4.88B
FNOXF Fortnox AB (publ)

N/A

USD 4.37B

ETFs Containing ZICX

ETP:CA First Trust Global Risk M.. 4.08 % 0.98 %

+0.20 (+0.00%)

CAD 0.01B
ZMU:CA BMO Mid-Term US IG Corpor.. 0.00 % 0.27 %

N/A

CAD 2.97B

Market Performance

  Market Performance vs. Industry/Classification (Software - Application) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.11% 66% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.11% 65% D 64% D
Trailing 12 Months  
Capital Gain 25.00% 71% C- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.00% 71% C- 74% C
Trailing 5 Years  
Capital Gain -95.76% 32% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.76% 32% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -32.73% 12% F 6% D-
Dividend Return -32.73% 12% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.53% 63% D 49% F
Risk Adjusted Return -63.51% 15% F 11% F
Market Capitalization 0.02B N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative earnings

The company had negative total earnings in the most recent four quarters.